N
LOGC

Nuveen’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Nuveen’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34,958
Closed -$254K – 3604
2021
Q1 		$254K Buy
34,958
+3,668
+12% +$30.2K ﹤0.01% 3200
2020
Q4 		$239K Buy
31,290
+1,672
+6% +$11.2K ﹤0.01% 3179
2020
Q3 		$269K Buy
29,618
+472
+2% +$3.58K ﹤0.01% 3106
2020
Q2 		$246K Buy
29,146
+10,428
+56% +$68.6K ﹤0.01% 3063
2020
Q1 		$92K Hold
18,718
– – ﹤0.01% 3073
2019
Q4 		$135K Hold
18,718
– – ﹤0.01% 3106
2019
Q3 		$202K Hold
18,718
– – ﹤0.01% 3122
2019
Q2 		$243K Buy
+18,718
New +$249K ﹤0.01% 3154

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Nuveen's LOGC Position: Q2 2021 in Review

Nuveen sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 34,958 shares — an estimated $254K sold.

Nuveen first reported a position in LOGC in Q2 2019 and held it in 8 quarters. The position peaked at $269K in Q3 2020. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • Nuveen reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 34,958 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $254K.
  • Nuveen first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • Nuveen's LogicBio Therapeutics, Inc. Common Stock position peaked at $269K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.